These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

659 related items for PubMed ID: 10788844

  • 1. Evaluation in an animal model and in vitro of the combination clavulanic acid and cephalosporins against beta-lactamase producing and nonproducing Staphylococcus aureus strains.
    de Sá Del Fiol F, Rocha De Mattos Filho T, Groppo FC.
    Braz J Infect Dis; 2000 Feb; 4(1):36-42. PubMed ID: 10788844
    [Abstract] [Full Text] [Related]

  • 2. Evaluation of restoration of sensitivities of resistant Staphylococcus aureus isolates by using cefuroxime and clavulanic acid in combination.
    Jalil A, Niazi ID, Khan SU.
    J Ayub Med Coll Abbottabad; 2008 Feb; 20(2):28-30. PubMed ID: 19385452
    [Abstract] [Full Text] [Related]

  • 3. Effect of beta-lactamase inhibitors on minimum inhibitory concentration of ampicillin and amoxicillin for Staphylococcus aureus strains.
    Paniagua GL, Monroy E, García O, Vaca S.
    Rev Latinoam Microbiol; 1998 Feb; 40(3-4):128-34. PubMed ID: 10932741
    [Abstract] [Full Text] [Related]

  • 4. Comparative evaluation of the in vitro activity of three combinations of beta-lactams with beta-lactamase inhibitors: piperacillin/tazobactam, ticarcillin/clavulanic acid and ampicillin/sulbactam.
    Sader HS, Tosin I, Sejas L, Miranda E.
    Braz J Infect Dis; 2000 Feb; 4(1):22-8. PubMed ID: 10788842
    [Abstract] [Full Text] [Related]

  • 5. Activity of selected antimicrobial agents against strains of Staphylococcus aureus isolated from bovine intramammary infections that produce beta-lactamase.
    Watts JL, Salmon SA.
    J Dairy Sci; 1997 Apr; 80(4):788-91. PubMed ID: 9149974
    [Abstract] [Full Text] [Related]

  • 6. Molecular correlation between in vitro and in vivo activity of beta-lactam and beta-lactamase inhibitor combinations against methicillin-resistant Staphylococcus aureus.
    Fasola EL, Fasching CE, Peterson LR.
    J Lab Clin Med; 1995 Feb; 125(2):200-11. PubMed ID: 7844469
    [Abstract] [Full Text] [Related]

  • 7. Hyperproduction of inhibitor-susceptible TEM beta-lactamase is responsible for resistance of Serratia marcescens to beta-lactam-beta-lactamase inhibitor combinations.
    Zhao WH, Hu ZQ, Chen G, Ito R, Shimamura T.
    Chemotherapy; 2008 Feb; 54(1):31-7. PubMed ID: 18063864
    [Abstract] [Full Text] [Related]

  • 8. Implications of beta-lactamase-inhibitor combinations.
    Fuchs PC, Barry AL.
    J Reprod Med; 1990 Mar; 35(3 Suppl):317-21. PubMed ID: 2319514
    [Abstract] [Full Text] [Related]

  • 9. Evolution of beta-lactamase inhibitors.
    Rolinson GN.
    Surg Gynecol Obstet; 1991 Mar; 172 Suppl():11-6. PubMed ID: 2024221
    [Abstract] [Full Text] [Related]

  • 10. Comparisons of parenteral broad-spectrum cephalosporins tested against bacterial isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (1998-2004).
    Jones RN, Sader HS, Fritsche TR, Pottumarthy S.
    Diagn Microbiol Infect Dis; 2007 Jan; 57(1):109-16. PubMed ID: 16930923
    [Abstract] [Full Text] [Related]

  • 11. In vitro study to compare sensitivity of amoxicillin+clavulanic acid and cefpodoxime+clavulanic acid among beta-lactamase positive clinical isolates of gram-positive and gram-negative pathogens.
    Pal RB, Pal P, Jain S, Kulkarni KP.
    J Indian Med Assoc; 2008 Aug; 106(8):545-8. PubMed ID: 18975519
    [Abstract] [Full Text] [Related]

  • 12. The vitro efficacy of beta-lactam and beta-lactamase inhibitors against multidrug resistant clinical strains of Mycobacterium tuberculosis.
    Dinçer I, Ergin A, Kocagöz T.
    Int J Antimicrob Agents; 2004 Apr; 23(4):408-11. PubMed ID: 15081094
    [Abstract] [Full Text] [Related]

  • 13. Potentiation of human polymorphonuclear leukocyte phagocytosis and intracellular bactericidal activity by amoxycillin/clavulanic acid.
    Cuffini AM, De Renzi G, Tullio V, Paizis G, Carlone NA.
    Drugs Exp Clin Res; 1996 Apr; 22(1):9-15. PubMed ID: 8839632
    [Abstract] [Full Text] [Related]

  • 14. The antibacterial activity of amoxycillin/clavulanic acid against Staphylococcus aureus ingested by human granulocytes.
    Cuffini AM, Tullio V, Allocco A, Paizis G, Carlone NA.
    Microbios; 1996 Apr; 87(350):31-8. PubMed ID: 8972100
    [Abstract] [Full Text] [Related]

  • 15. In vitro activity of ceftriaxone plus tazobactam against members of Enterobacteriaceae.
    Prakash SK, Arora V, Prashad R, Sharma VK.
    J Assoc Physicians India; 2005 Jul; 53():595-8. PubMed ID: 16190126
    [Abstract] [Full Text] [Related]

  • 16. In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes.
    Mushtaq S, Warner M, Ge Y, Kaniga K, Livermore DM.
    J Antimicrob Chemother; 2007 Aug; 60(2):300-11. PubMed ID: 17548456
    [Abstract] [Full Text] [Related]

  • 17. Orthodox and unorthodox clavulanate combinations against extended-spectrum beta-lactamase producers.
    Livermore DM, Hope R, Mushtaq S, Warner M.
    Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():189-93. PubMed ID: 18154546
    [Abstract] [Full Text] [Related]

  • 18. A comparative study of the activity of first and second generation cephalosporins and their combinations with beta-lactamase inhibitors against Bacteroides fragilis.
    Martin MA, Liebana J, Castillo AM, Gutierrez J, Piédrola G.
    Microbios; 1991 Jan; 67(272-273):195-202. PubMed ID: 1779879
    [Abstract] [Full Text] [Related]

  • 19. Role of beta-lactamase inhibitors in enterobacterial isolates producing extended-spectrum beta-lactamases.
    Bhattacharjee A, Sen MR, Prakash P, Anupurba S.
    J Antimicrob Chemother; 2008 Feb; 61(2):309-14. PubMed ID: 18174199
    [Abstract] [Full Text] [Related]

  • 20. Development of beta-lactamase inhibitors.
    Sutherland R.
    J Reprod Med; 1990 Mar; 35(3 Suppl):307-12. PubMed ID: 2319512
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.